Remove

PICOSSIBLE (04-03)
Approved for use through 07/10/2008 (04/03)
Approved for use through 07/10/2008 (04/03) (04/03)
U.S. Peletra att (14/04/maid 07/04/10/04)
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of infamination unless of contains a value of the office of the original of the original to a contains a value of the original of the original of the original origina

	Application Number		10564118		
NEODIATION DIOCE COURT	Filing Date		2006-01-10		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Lotha		ar A BRASSARD		
	Art Unit				
	Examiner Name				
	Attorney Docket Numb	er.	683105-1US cBT001/2003US		

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Pat of cited Docu	entee or Applicant urnent		Columns,Lines where nt Passages or Relev Appear	
	1	6204033	B1	2001-03-20	Detlef Muller-	Schulte			
	2	6942806	B2	2005-09-13	Matthias FRA	NZREB et al.			
	3	6139736		2000-10-31	Mitsuru INAB	A			
	4	6942806	B2	2005-09-13	Matthias Fran	nzreb et al.			
If you wis	h to a	dd additional U.S. Pater	t citatio	n information ;	please click the	Add button.		Add	
			U.S.P	ATENT APPL	ICATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant		Columns,Lines where nt Passages or Relev Appear	
	1	20040159612	A1	2004-08-19	Matthias Fran	zreb et al			
If you wis	h to a	d additional U.S. Publis	shed Ap	plication citati	on information	please click the Ad	d button.	Add	_
				FOREIGN PA	TENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No		Country Code ²		Publication Date	Name of Patente Applicant of cited Document	eor wi	ages,Columns,Lines here Relevant assages or Relevant igures Appear	TS

	1	100 63 984	DE	A1	2002-06-20	BILATEC Gesellschaft zur Entwicklung	English translation of Abstract only	Z
	2	296 14 623	DE	U1	1997-02-06	AGOWA Gesellschaft für molekularbiologische	English translation of Abstract only	Ø
	3	195 28 029	DE	A1	1997-02-06	Dr. Detlef Muller-Schulte		
	4	100 57 396	DE	C1	2002-04-04	Forschungszentrum Karlsruhe GmbH		
	5	01/68263	wo	A1	2001-09-20	Thermo Labsystems Oy		
	6	101 17 659	DE	A1	2002-10-17	Steinert Elektromagnetbau GmbH		
	7	932 621	DE		1955-09-05		English translation of Abstract only	Z
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner	Cite					the article (when appropriate, pages(s), volume-is		Тs

Examine Cito Include name of the author (in CAPITAL LETTERS), tills of the article (when appropriate), tills of the item Initials* No Dischargazine, pursuals serial symposium, catalog, etc), date, pages(s), volume-issue number(s).

1 If you wish to add additional non-patent literature document clation information please click the Add button Add

Application Number 10564118		
Application Humber 10004110		
Filing Date 2006-01-10		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor Lothar A BRASSARD	ar A BRASSARD	
(Not for submission under 37 CFR 1.99)		
Examiner Name		
Attorney Docket Number 683105-1US cBT001/2003US		

EXAMINER SIGNATURE						
Examiner Signature		Date Considered				
*FXAMINER: Initial if	reference considered, whether or not citation is in conforms	non with MDED 600	Draw line through a			

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kin Codes of USPTO Patent Documents at wark USPTO,GDY or MPEP 901.54. * Eater office that issued the document, by the two-letter code (WIPO Standard STS). * The Jupanese plant documents, the valuation of the year of the register of the Director must precise the sent number of the patent document. Program of the Patent STS of the

Attorney Docket Number 6

10000 000 01 01 11 1101 01	na maa ta mana ara appropriata sana	eon(o).	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1,17 (p) has been submitted herewith.

Diagon one 37 CER 1 07 and 1 98 to make the appropriate colortion(c)

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/WILLIAM W. SCHWARZE/	Date (YYYY-MM-DD)	2006-06-16					
Name/Print	William W. Schwarze	Registration Number	25,918					

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is fol file and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.32.11.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.2.11.450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.